/ /

CLINICAL

Interventions to improve quality of life for patients with psoriasis and psoriatic arthritis
Interventions to improve quality of life for patients with psoriasis and psoriatic arthritisThe goal of this activity is to educate pharmacists and pharmacy technicians about pharmacist interventions in improving the quality of life for patients with psoriasis and psoriatic arthritis. Readers will also gain knowledge about available options for treatment, adverse effects, risks, and benefits.
Beyond the plaqueThere’s good evidence to suggest dermatologists who assess psoriasis patients should look beyond the plaques on the skin and consider not just the increased risk to the joints, but also the heart, mind and more.
The oral pipeline for psoriasisOral options in the pipeline for psoriasis show promise.
Facial care advice for patients with acne
Facial care advice for patients with acneFacial care advice for patients with acne While both benzoyl peroxide acne preparations and vitamin C products carry benefits in acne treatment, it’s wise to recall the characteristics of each element in advising patients on caring for their skin. Vitamin C is rapidly oxidized with exposure to air. Benzoyl peroxide is an oxidant. This is how Dr. Draelos suggests these products be used.
Combination therapy shows promising phase 2 resultsData suggest photodynamic therapy with the investigational topical methyl aminolevulinate may be an effective treatment for patients with severe facial acne.
Can stress cause skin disease?Science is finally catching up to common sense when it comes to the idea that stress worsens skin conditions.
Ixekizumab effective psoriasis treatment through 60 weeksResults from three phase 3 trials, suggest ixekizumab (Talz, Eli Lilly & Company) is effective through 60 weeks of treatment among patients with moderate-to-severe plaque psoriasis.
App aims to supplement physician visits for acneThe acne app offers a free and immediate analysis of acne type and severity; develops an individualized acne control plan; and monitors users’ progress. It aims to help consumers diagnose, treat, manage and prevent acne.
Investigative eczema drug shows positive phase 2 resultsUK-based Ziarco Pharma Ltd. recently announced positive phase 2a results for ZPL-389, a once daily oral histamine H4 receptor antagonist, for the treatment of moderate to severe atopic dermatitis.
Dupilumab demonstrates promising resultsThe systemic therapy dupilumab met primary endpoints in two phase 3 studies on adults with in inadequately controlled moderate-to-severe atopic dermatitis.

Poll

View Results